Related Experiment Video

Updated: Jun 1, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The ezetimibe controversy: implications for clinical practice

Ujjaini Khanderia1, Randolph E Regal, Melvyn Rubenfire

  • 1College of Pharmacy and Department of Pharmacy Services, University of Michigan, Ann Arbor, Michigan 48109-5008, USA. shamo@med.umich.edu

Therapeutic Advances in Cardiovascular Disease
|June 4, 2011
PubMed

Insights

Ezetimibe effectively lowers LDL-C, but its role in cardiovascular risk reduction is debated due to mixed trial results. Ongoing studies will clarify its clinical benefits, especially in high-risk patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Low-density lipoprotein cholesterol (LDL-C) is a primary target for lipid-lowering therapy.
  • Statins alone may not achieve LDL-C goals, necessitating adjunctive therapies for cardiovascular risk reduction.
  • Ezetimibe inhibits intestinal cholesterol absorption and lowers LDL-C, non-HDL-C, and ApoB.

Purpose of the Study:

  • To review trials contributing to the ezetimibe controversy.
  • To discuss ezetimibe's potential role in specific patient populations.
  • To contextualize findings pending results from ongoing clinical trials.

Main Methods:

  • Review of randomized controlled trials on ezetimibe efficacy and safety.
  • Analysis of studies investigating atherosclerotic plaque regression (carotid intima-media thickness).
  • Examination of clinical event data from trials in acute coronary syndrome and chronic kidney disease patients.

Main Results:

  • Ezetimibe effectively lowers LDL-C, non-HDL-C, and ApoB, alone or with statins.
  • Mixed results exist regarding atherosclerotic plaque regression and concerns about cancer risk.
  • A trial in chronic kidney disease patients showed reduced clinical events with ezetimibe/simvastatin combination.

Conclusions:

  • Ezetimibe's role in lipid therapy is debated due to conflicting evidence.
  • Ongoing trials, including a large study in high-risk acute coronary syndrome patients, are crucial.
  • Ezetimibe may have a role in specific patient groups pending further evidence.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...